Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.22.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenue:    
Contract research revenue $ 33,333 $ 158,333
Costs and Expenses:    
Research and development 14,583,283 14,358,918
General and administrative 10,184,805 10,005,967
Total costs and expenses 24,768,088 24,364,885
Loss from operations (24,734,755) (24,206,552)
Sale of New Jersey net operating loss 1,328,470 1,073,289
Other income, net 122,870 686,425
Net loss (23,283,415) (22,446,838)
Preferred stock series B accumulated dividends (395,799) (793,442)
Net loss attributable to common shareholders $ (23,679,214) $ (23,240,280)
Net loss attributable to common shareholders per share – basic and diluted $ (0.11) $ (0.12)
Basic and diluted 210,178,332 196,894,628
Other comprehensive (loss)/income, net of tax    
Net unrealized (loss)/gain on securities available-for-sale $ (373,671) $ 237,537
Reclassification of realized gain on securities available-for-sale to net loss (8,485)
Other comprehensive (loss)/income, net of tax (373,671) 229,052
Comprehensive loss attributable to shareholders $ (23,657,086) $ (22,217,786)